CRDL
vs
S
S&P TSX Composite Index (Canada)
CRDL
Over the past 12 months, CRDL has underperformed S&P TSX Composite Index (Canada), delivering a return of -23% compared to the S&P TSX Composite Index (Canada)'s +25% growth.
Stocks Performance
CRDL vs S&P TSX Composite Index (Canada)
Performance Gap
CRDL vs S&P TSX Composite Index (Canada)
Performance By Year
CRDL vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cardiol Therapeutics Inc
Glance View
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.